TREATING TO TARGET WITH CANAKINUMAB IN PATIENTS WITH ACTIVE SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE LONG-TERM EXTENSION THE PHASE III PIVOTAL TRIAL

被引：0
|
作者：
Ruperto, N. [1 ]
Brunner, H. I. [2 ]
Quartier, P. [3 ]
Constantin, T. [1 ]
Alexeeva, E. [1 ]
Kone-Paut, I. [4 ]
Marzan, K. [1 ]
Wulffraat, N. [1 ]
Schneider, R. [2 ]
Padeh, S. [1 ]
Chasnyk, V. [1 ]
Wouters, C. [1 ]
Kuemmerle-Deschner, J. B. [1 ]
Kallinich, T. [1 ]
Lauwerys, B. [5 ,6 ]
Haddad, E. [2 ]
Nasonov, E. [1 ]
Trachana, M. [1 ]
Vougiouka, O. [1 ]
Leon, K. [7 ]
Speziale, A. [8 ]
Lheritier, K. [8 ]
Martini, A. [1 ]
Lovell, D. [2 ]
机构：
[1] PRINTO Ist Gaslini, Genoa, Italy
[2] PRCSG, Cincinnati, OH USA
[3] Necker Enfants Malad Hosp, Paris, France
[4] Hop Bicetre, Paris, France
[5] Clin Univ St Luc, Brussels, Belgium
[6] Catholic Univ Louvain, Brussels, Belgium
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Novartis Pharma AG, Basel, Switzerland
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2016年 / 75卷
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1136/annrheumdis-2016-eular.2658
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0579
引用
收藏
页码：401 / 402
页数：2
相关论文
共 50 条
  • [21] Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry
    Giancane, Gabriella
    Papa, Riccardo
    Vastert, Sebastiaan
    Bagnasco, Francesca
    Swart, Joost F.
    Quartier, Pierre
    Anton, Jordi
    Kamphuis, Sylvia
    Sanner, Helga
    Glerup, Mia
    De Benedetti, Fabrizio
    Tsitsami, Elena
    Remesal, Agustin
    Moreno, Estefania
    De Inocencio, Jaime
    Myrup, Charlotte
    Pallotti, Chiara
    Kone-Paut, Isabelle
    Franck-Larsson, Karin
    Malmstrom, Hakan
    Cederholm, Susanna
    Pistorio, Angela
    Wulffraat, Nico
    Ruperto, Nicolino
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (04) : 398 - 407
  • [22] Clinical benefits of donepezil: Results from a long-term phase III extension trial
    Doody, RS
    Pratt, RD
    Perdomo, CA
    NEUROLOGY, 1999, 52 (06) : A174 - A174
  • [23] Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study
    Brunner, Hermine, I
    Quartier, Pierre
    Alexeeva, Ekaterina
    Constantin, Tamas
    Kone-Paut, Isabelle
    Marzan, Katherine
    Schneider, Rayfel
    Wulffraat, Nico M.
    Chasnyk, Vyacheslav
    Tirosh, Irit
    Kallinich, Tilmann
    Kuemmerle-Deschner, Jasmin
    Wouters, Carine
    Lauwerys, Bernard
    Nikishina, Irina
    Trachana, Maria
    Vougiouka, Olga
    Martini, Alberto
    Lovell, Daniel J.
    Levy, Jeremy
    Vritzali, Eleni
    Ruperto, Nicolino
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 (12) : 2147 - 2158
  • [24] Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis: 48-week results from an open-label phase III study in Japanese patients
    Nishimura, Kenichi
    Hara, Ryoki
    Umebayashi, Hiroaki
    Takei, Syuji
    Iwata, Naomi
    Imagawa, Tomoyuki
    Shimizu, Masaki
    Tomiita, Minako
    Seko, Noriko
    Kitawaki, Tetsuji
    Yokota, Shumpei
    MODERN RHEUMATOLOGY, 2021, 31 (01) : 226 - 234
  • [25] A Moving Target: Lessons From Long-Term Studies in Juvenile Idiopathic Arthritis
    Guzman, Jaime
    Petty, Ross E.
    ARTHRITIS CARE & RESEARCH, 2022, 74 (05) : 716 - 718
  • [26] Long-term outcome in patients with juvenile idiopathic arthritis
    Minden, K
    Niewerth, M
    Listing, J
    Biedermann, T
    Bollow, M
    Schöntube, M
    Zink, A
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : 2392 - 2401
  • [27] LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): 5-YEAR FOLLOW-UP OF AN OPEN-LABEL TRIAL
    Ruperto, N.
    Brunner, H. I.
    Quartier, P.
    Constantin, T.
    Alexeeva, E.
    Schneider, R.
    Kone-Paut, I.
    Schikler, K.
    Marzan, K.
    Wulffraat, N.
    Padeh, S.
    Chasnyk, V.
    Wouters, C.
    Kuemmerle-Deschner, J. B.
    Kallinich, T.
    Lauwerys, B.
    Haddad, E.
    Nasonov, E.
    Trachana, M.
    Vougiouka, O.
    Leon, K.
    Speziale, A.
    Lheritier, K.
    Martini, A.
    Lovell, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 265 - 266
  • [28] Phase III Study Results on the Efficacy and Safety of Canakinumab, a Long-Acting, Fully Human Anti-Interleukin-1β Antibody, in Systemic Juvenile Idiopathic Arthritis with Active Systemic Features.
    Brunner, Hermine
    Ruperto, Nicolino
    Horneff, Gerd
    Quartier, Pierre
    Constantin, Tamas
    Berkun, Yackov
    Kallinich, Tilmann
    Brik, Riva
    Ferrandiz, Manuel A.
    Lheritier, Karine
    Preiss, Ralph
    Tseng, Lillian
    Lovell, Daniel J.
    Martini, Alberto
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1030 - S1030
  • [29] EVALUATION OF EFFICACY AND SAFETY OF CANAKINUMAB IN JAPANESE PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS IN PHASE III CLINICAL TRIAL, COMPOSED PREDOMINANTLY OF PATIENTS WITH PRIOR USE OF TOCILIZUMAB
    Takei, S.
    Hara, R.
    Umebayashi, H.
    Iwata, N.
    Imagawa, T.
    Shimizu, M.
    Tomiita, M.
    Seko, N.
    Kitawaki, T.
    Wang, G.
    Yokota, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 499 - 500
  • [30] LONG - TERM OUTCOMES IN ADULT PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
    Kiseleva, E.
    Koltsova, E.
    Volnukhin, E.
    Savenkova, N.
    Klimets, A.
    Rozochkina, E.
    Kovshik, A.
    Lukina, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 993 - 993
12345